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doi:10.1016/j.ejvs.2008.06.002Abstract Our understanding of the events that occur within atherosclerotic plaques has im-
proved dramatically over the last 2 decades, particularly with regard to the role of plaque de-
stabilisation and the onset of clinical ischaemic syndromes. Many potential targets have been
identified for therapeutic intervention aimed at disease prevention, plaque stabilisation and
regression. Furthermore, many potential biomarkers of vascular disease have generated inter-
est in terms of monitoring disease activity and the effect of therapeutic agents. However, de-
spite much scientific promise with in vitro cell and animal models, there has been much less
success in modulation of these processes in clinical practice. This review will highlight the local
and systemic factors associated with disease progression and acute plaque destabilisation, the
current role of therapeutic agents and the potential for targeted plaque modification.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
The ‘vulnerable plaque’ concept
Atherosclerosis begins in childhood, but it takes decades to
evolve into the mature plaques responsible for the onset of
ischaemic symptoms. While plaque growth due to smooth
muscle cell proliferation, matrix synthesis and lipid accu-
mulation may narrow the arterial lumen and ultimately
limit blood flow, uncomplicated atherosclerosis is largely253205; fax:þ442087253475.
es.nhs.uk (I. Loftus).
ty for Vascular Surgery. Publishea benign disease. The final clinical outcome depends on
whether a plaque becomes unstable, leading to acute
disruption of the surface and exposure of the thrombogenic
core to luminal blood flow (Figs. 1 and 2). The concept of
the ‘vulnerable plaque’ was initially described in 1990
and is now largely accepted.1
The vital question in plaque pathogenesis is why, after
years of indolent growth, life-threatening disruption and
subsequent thrombosis should suddenly occur. Plaque
stabilisation may prove to be an important clinical strategy
for preventing the development of complications. By
identifying ‘vulnerable’ plaques we can direct pharmaco-
therapy to those most likely to benefit, and by understand-
ing the mechanisms of plaque rupture, strive to develop
new treatments aimed at prevention.d by Elsevier Ltd. All rights reserved.
Figure 1 Potentially unstable carotid plaque demonstrating
thin fibrous cap and lipid rich core.
508 I. Loftus, M. ThompsonPlaque disruption: from inflammation to
biomarkers
Basic research in plaque biology over the last 20 years has
identified a large number of factors linked to the pro-
gression of atherosclerosis, and particularly associated with
acute plaque disruption (Fig. 3). Our understanding of the
pathogenesis of atherosclerotic lesions has improved dra-
matically (Fig. 4). In particular it is now well established
that inflammation is a key feature in all stages of the dis-
ease, especially in the destabilisation of the plaque which
leads to plaque rupture.2 Several cell types within the
plaque, in particular monocyte derived macrophages and
T-lymphocytes, are known to produce a large range of fac-
tors including cytokines, chemokines, proteolytic enzymes,
growth factors and disintegrins which perpetuate a cycle of
endothelial cell activation, smooth muscle cell prolifera-
tion, lipid deposition, inflammation and lesion progression,
culminating in acute plaque destabilisation. Many of these
factors are also detectable systemically and have been
hypothesised as markers of atherosclerosis and plaque in-
stability. While some of these factors appear to be indepen-
dent of traditional risk factors, and some may ultimately
prove to be useful as biomarkers for risk of disease progres-
sion and clinical events, they do not necessarily represent
targets for pharmacotherapy. Numerous associations have
been made, and targets suggested for pharmacotherapy,Figure 2 Unstable carotid plaque with evidence of ulcera-
tion, cap rupture and thrombus formation.but few have demonstrated real promise in terms of disease
prevention or regression. Strategies such as vaccination
against antigens promoting atherogenesis, cyclooxygenase
inhibitors, statins and ACE inhibitors may reduce the levels
of inflammatory markers and other potential targets, but
their impact on overall cardiovascular risk is largely
unknown.3
A recent review has highlighted the pressure on the
pharmaceutical industry to accelerate the rate of bringing
new cardiovascular therapeutic agents onto the market-
place, and the subsequent interest in biomarkers of disease
severity.4 The accepted definition of a biomarker is ‘a char-
acteristic that is objectively measured and evaluated as an
indicator of normal or pathogenic processes or as a physio-
logical response to a therapeutic intervention’.5 Bio-
markers such as carotid-intima thickness, LDL-cholesterol
and CRP have recently been put under the spotlight with
the disappointing results of the ENHANCE study of com-
bined simvastatin/ezetemibe, and the halting of the JUPI-
TER trial of rosuvastatin in patients with normal LDL
levels but raised CRP.4 This raises the issue of which- if
any- of the established and proposed biomarkers of cardio-
vascular disease, are valuable surrogate endpoints.Targets for Plaque Modification
A variety of intrinsic and extrinsic factors predispose
a plaque to instability and acute disruption. Intrinsic
features that characterize a plaque as vulnerable are lipid
content, increased inflammatory cell infiltration (particu-
larly macrophages), foam cells and T lymphocytes content
and a reduced collagen and smooth muscle cell content
associated with increased proteolysis.6,7 Plaque rupture
tends to occur at the shoulder region, associated with cap
thinning and macrophage infiltration.8 The shoulder region
is the area of the plaque exposed to the greatest shear
stress.9 The lipid pool has poor tensile strength, decreasing
load-bearing capabilities, resulting in increased stress in
the overlying fibrous cap.10 Extrinsic features that predis-
pose a plaque to rupture, particularly coronary plaques, in-
clude increased blood pressure and vasospasm. Acute
myocardial infarction has been associated with trigger
events, including emotional stress and physical activity,
probably related to blood pressure and vasospasm.11
Potential therapeutic strategies to achieve plaque sta-
bilization have targeted these intrinsic or extrinsic features
that promote plaque rupture.12 Lipid lowering agents, anti-
oxidants, b-adrenergic blockers and angiotensin converting
enzyme inhibitors have been shown to reduce the incidence
of acute coronary syndromes, presumably through plaque
stabilization. Strategies promoting extra cellular matrix
synthesis or preventing degradation within the plaque, as
well as more novel gene therapy approaches may show
promise in achieving plaque stabilization. More complex
manipulation of plasma lipid levels through administration
of systemic HDL is also under investigation.
One of the major advances in risk modification over
recent years has been the development and widespread
uptake of HMG-CoA Reductase inhibitors. Designed as lipid
lowering therapy, it is now clear that they have pleiotrophic
effects independent of their lipid lowering effects. The
Figure 3 Histological sections of carotid plaques revealing features of plaque instability. H&E stained (a) carotid plaque with
intraplaque haemorrhage (IPH), and EVG stained (b) plaque rupture (PR), (c) plaque cap thinning (PCT), and (D) plaque necrosis
(PN). Magnification  10.
Plaque Biology 509absolute degree of protection this equates to and precise
plaque stabilisation effect, in addition to improvements in
the lipid profile, is difficult to establish.13
Evolution of the Unstable Plaque
In the early 1970’s Ross postulated that atherogenesis was
dependent upon cellular interactions in the vessel wall
following endothelial injury. The premise that atherogen-
esis represents a multi-staged exaggerated response to
injury has evolved into an attractive unifying hypothesis of
vascular disease and repair. Each step and each component
of the pathway represents a potential target for interven-
tion. Vessel damage is initiated by diverse insults including
infectious agents, nicotine, homocysteine and oxidised-LDL
through a direct injurious effect upon the vessel
endothelium.14
Endothelial activation in response to injurious agents
results in surface expression of cell adhesion molecules,
including VCAM-1, ICAM-1, E-selectin and P-selectin, which
permit leucocyte binding. Activated endothelial cells
express chemo attractant cytokines such as MCP-1, MCSF,
IL-1, IL-6 and TNF-a, creating a pro-inflammatory environ-
ment.15,16 This, in conjunction with the increased perme-
ability of the endothelium, mediates intimal migration of
inflammatory cells. Within the vessel wall, activated
inflammatory cells release a potent array of cytokines and
growth factors, stimulating the intimal migration and pro-
liferation of vascular smooth muscle cells. Furthermore,
marrow-derived progenitor cells migrate to the site of in-
jury where they adapt into endothelial or smooth musclecell phenotypes. Stimulated smooth muscle cells produce
extra cellular matrix with the subsequent formation of
the fibrous plaque.
More mature, and potentially unstable lesions, develop
as macrophages and smooth muscle cells accumulate lipid.
A large lipid core is a hallmark of the unstable plaque,
though the variability in plaque composition is poorly
understood. Larger proportions of disrupted coronary
plaques are occupied by lipid core than stable plaques,
and 90% of thrombosing aortic plaques versus 11% of intact
plaques exhibit a lipid core that occupied >40% of total
lesion volume.6
While this oversimplifies the myriad of positive and
negative feedback loops throughout all stages of plaque
development, destabilisation and rupture, it serves as
a rough template from which to approach therapeutic
strategies.
Inflammation: The Process Behind the Targets
The concept that atherosclerosis is an inflammatory phe-
nomenon is supported by both experimental and clinical
observations. Examination of plaques from the coronary and
carotid circulation demonstrates up regulation of an array of
growth factors and cytokines.17 As mentioned previously,
some of these have been suggested as serum markers of sys-
temic inflammation and correlated with risk of clinical
events.18 Much of the work regarding inflammatory markers
has related to cardiac events, though there seems to be
considerable overlap with carotid risk. Markers which have
received particular attention include fibrinogen, serum
Figure 4 The stages of plaque provide numerous potential targets for pharmacotherapy. Endothelial damage allows passage of
inflammatory cells and LDL into the vessel intima; free radicals are responsible for oxidation of the deposited LDL; oxidized-LDL
promotes cytokine and protease release from macrophages; proteases degrade the fibrous cap causing disruption; exposure of
the thrombogenic core to the blood results in clot formation; local thrombotic and fibrinolytic activity determine the degree of
thrombus progression or dissolution.
510 I. Loftus, M. Thompsonamyloid A and C-reactive protein (CRP).15 The Cholesterol
and Recurrent Events Study demonstrated a positive correla-
tion between increased levels of serum amyloid A and CRP
and recurrent coronary events.19 CRP levels are associated
with increased cardiovascular risk in apparently healthyindividuals.20 Increased relative risk was also identified
with serum amyloid A, soluble intracellular adhesion mole-
cule-1, interleukin-6, homocysteine, apolipoprotein B-100
and total and LDL cholesterol levels. Other potential
predictors of coronary risk include phospholipase A2,
Plaque Biology 511myeloperoxidase and soluble CD-40 ligand. The relative im-
portance of thesemarkers andwhether they present specific
targets for therapy remains to be seen.C - Reactive Protein: A Marker or a Target?
CRP is a dominant acute phase protein associated with
infection. Since a commercially available quantitative
assay became available in the 1980’s, there has been
mounting evidence of an association between CRP and
severity of atherosclerosis or cardiovascular risk.21e23
Several studies have demonstrated an association be-
tween CRP and acute myocardial infarction and adverse
outcome. In patients with angina, a raised CRP predicts an
increased risk of MI and sudden cardiac death.24 It may also
be predictive of increased cardiovascular risk in asymptom-
atic patients. Ridker and co-workers demonstrated that
baseline CRP levels in apparently healthy men, predicted
future risk of developing symptomatic peripheral arterial
disease.25
CRP does not only represent a marker of risk, but also
a potential target for therapy. CRP enhances cell-medi-
ated immunity, promoting phagocytosis, chemotaxis and
activating the complement cascade and circulating plate-
lets. Traditionally antiplatelet agents and statins have
represented the mainstay of cardiovascular risk preven-
tion. An evolving pharmacological paradigm links these
agents to serum CRP levels. While there is considerable
evidence linking aspirin with reductions in cardiac mor-
tality, it is now apparent that the benefit of anti-platelet
therapy is greatest in healthy males with high CRP
levels.26 This may reflect a direct impact on endothelial
dysfunction and CRP production, but the reduction in
CRP may simply act as a marker of the efficacy of aspirin
(as a preventative treatment) rather than having a direct
impact on risk reduction through CRP per se.
Similarly, a number of studies have demonstrated an
attenuation of CRP levels with statins. The Oxford Heart
Protection Study demonstrated a clear benefit in terms of
reducing cardiac and peripheral vascular risk which was
independent of lipid levels.27 This is likely to represent
lipid-independent plaque stabilising actions including anti-
proteolytic and anti-inflammatory properties. Independent
of lipid lowering, statins have been shown to significantly
reduce CRP levels and be effective in risk reduction in pa-
tients with low cholesterol but high CRP.28,29 Statins in-
crease nitric oxide synthase activity30 and promote
endothelial passivation which is a direct reduction in cellu-
lar adhesion molecules interfering with inflammatory cell
adherence to the endothelium.31 Nitric oxide is a potent va-
sodilator but also causes inhibition of smooth muscle cell
proliferation and platelet aggregation.
The precise mechanisms by which aspirin and statins
reduce CRP remain unclear, and the ‘chicken-and-egg’
argument (once again) applies. It is unknown whether there
is a direct effect on CRP production, and whether this in turn
affects cardiovascular risk, or whether the observed effect is
secondary to the well-documented anti-inflammatory ef-
fects. The importance of this relationship is debatable. Of all
risk prediction markers, CRP may be the most useful- and (in
terms of patient care), whether the effect is primary orsecondary may prove irrelevant. The JUPITER trial of
rosuvastatin in patients with raised CRP and normal choles-
terol has yet to be published and may help us to better
define the role of CRP as a surrogate endpoint for cardio-
vascular trials.
Cytokines and Growth Factors
Inflammatory mediators represent a diverse group of
peptides which can be classified as growth (PDGF, FGF,
EGF, IGF, VEGF), chemokine (MCP, MIP, IL-8,), pro-
inflammatory (IL-1,-2,-6,-12,-13, IFN, TNF) and anti-
inflammatory factors (TGF, IL-4,-10-12), though many
are multifunctional.32
The interrelationship between this vast array of factors
is highly complex and it is overly simplistic to assume that
each represents a potential target for pharmacotherapy.
Various studies have attempted to manipulate the athero-
genetic process, particularly in animal models (such as
gene-knockout mice) with promising results. IL-10 for
example, is a pluripotent cytokine which down regulates
adhesion molecule expression and inhibits smooth muscle
cell proliferation. In vivo studies suggest that IL-10 effec-
tively reduces post-injury intimal hyperplasia.33 However,
translation to clinical practice has been less successful.
Growth factors and cytokines regulate numerous steps in
atherosclerosis, often working synergistically to exert their
influences on the vessel wall. Because of the functional re-
dundancy inherent among inflammatory mediators, strate-
gies aimed at targeting single substances seem unlikely to
succeed clinically.
Broad-based anti-inflammatory agents, however, may be
more promising, and the clinical effects of statins and
salicylates may, at least in part, be related to a shift in the
balance of pro- and anti-inflammatory factors.
Targeting the Stimuli to Atherogenesis
As mentioned previously, salicylates and statins are in-
herently anti-inflammatory, effecting expression of adhe-
sion molecules, cytokines and inflammatory transcription
factors. Their effects in risk reduction may occur at many
levels of the inflammatory pathway; indeed our knowledge
of the inflammatory ‘response to injury’ process creates
many potential targets to attenuate the progression of the
disease. While the goals of interventions are sound, the
clinical translation of these goals at many levels has yet to
be realised.
Primary and secondary prevention trials have clearly
documented the benefit of traditional risk factor modifica-
tion which is beyond the realms of this review. However,
there are a number of areas which deserve attention, in
particular the role of lipids, infectious agents and
homocysteine.
Lipid Modification: Looking Beyond Statins
The effects of statins on LDL and HDL levels are well
documented. Traditional therapy has been aimed at
reducing LDL deposition and augmenting LDL removal,
512 I. Loftus, M. Thompsonbut other targets may prove clinically valuable. Oxidation
of LDL within the plaque induces monocytes and foam cell
formation with subsequent apoptosis and free radical
release. Oxidised LDL and reactive oxygen species are
directly injurious to vascular cells including the endothe-
lium; they promote platelet aggregation and inflammatory
cell adhesion and stimulate smooth muscle cell prolifer-
ation.34 Antioxidants inhibit oxidation of LDL; they coun-
teract the effect of reactive oxygen species and may
promote plaque stabilisation through a reduction in ma-
trix degradation. In animal models, antioxidants have
been shown to decrease the expression of MMP-9, one of
the major proteolytic enzymes implicated in acute plaque
disruption, and prevent intimal hyperplasia after vessel
balloon injury.35,36
Epidemiological studies of antioxidant vitamins have also
suggested a benefit, particularly for Vitamin E. In large
cohort studies, people with a high dietary intake of Vitamin
E demonstrated a lower long term risk of clinical coronary
disease.37,38 However, clinical trials in patients with proven
coronary disease have demonstrated conflicting results.39,40
More recently antioxidant gene therapy has been trialled
to augment antioxidant defence therapies, again with
conflicting results.41 It may be that such therapy must be
directed very early in the disease process to maximise
anti-atherogenic potential.
HDL therapy may also offer benefit, both in terms of long
term prevention and also in the latter stages of atheroscle-
rotic disease, particularly in acute plaque stabilisation.
Current approaches to therapy include acute HDL infusion
therapy in acute coronary syndrome42 and acute carotid in-
stability, and long term oral therapy.43 In coronary disease,
short term HDL infusions have been demonstrated to alter
plaque characterisation and severity of disease on angiog-
raphy. Increased circulating HDL also has a profound effect
on macrophage number and activity. This may well be mul-
tifactorial and further work is required to elucidate the
short and long term benefit of such therapy.
Gene therapy strategies have included increasing HDL
and decreasing LDL levels. Animal models demonstrate
effective gene transfer with reductions in circulating
cholesterol and increase in serum HDL respectively. How-
ever, studies in humans again are at an early stage and
results thus far are less promising.12Homocysteine
Homocysteine is an amino acid formed from methionine in
animal and plant proteins. Levels rise in certain genetic
conditions or vitamin deficiencies. Homocysteine is itself
not harmful, but is rapidly oxidised in plasma and tissue
macrophages releasing reactive oxygen species and initiat-
ing, or promoting, inflammation. Hyperhomocysteinaemia
is associated with increased kevels of platelet aggregation,
abnormalities of fibrinolysis, endothelial cell dysfunction,
LDL oxidation and smooth muscle cell proliferation. Nu-
merous observational studies have demonstrated a link with
atherosclerosis.44
Folic acid, vitamins B12 and B6, and pyridoxine are impor-
tant cofactors involved in the processing of homocysteine
and food supplementation has become routine. However,reductions in homocysteine in clinical trials have failed to
show benefits in term of reducing cardiovascular risk. Recent
studies have shown that statins have a direct effect on homo-
cysteine-induced endothelial adhesiveness through inhibi-
tion of vascular cell adhesion molecule-1, though again the
clinical relevance of this is unclear.45Infectious Agents: An Association or Causation?
The role of infectious agents in atherosclerosis remains
controversial. Definitive proof of a causal relationship is
lacking, although studies have reported associations be-
tween plaque development and a variety of agents in-
cluding Chlamydia pneumoniae, Helicobacter pylori and
cytomegalovirus.46e48
Certain infectious agents can evoke cellular and molec-
ular changes supportive of a role in atherogenesis. Work has
shown that chlamydial interaction with monocytes results
in up-regulation of TNF-a and IL-b, both of which are
associated with plaque development.49,50 Chlamydial pro-
duction of HSP60 antigen activates human vascular endo-
thelium, and increases TNF-a and MMP expression in
macrophages.51
There remain doubts about the methods employed for
Chlamydia detection and the overall prevalence of the
organism makes it difficult to determine its true role.
Eradication trials have further muddied the waters because
it is apparent that antibiotics may exert influences in-
dependent of their anti-microbial effects. The STAMINA trial
demonstrated that eradication therapy (amoxicillin/azi-
thromycin, metronidazole and omeprazole) administered
for 1 week after an acute coronary syndrome, significantly
reduced death and acute coronary syndrome readmission
rates in the following 12 months.52 These effects were unre-
lated to seropositivity rate for both Chlamydia and Helico-
bacter. The WIZARD Trial (azithromycin versus placebo for
12 weeks) demonstrated no clinical benefit from Chlamydia
eradication in a large cohort of 7747 adults in terms of the
clinical sequelae of coronary heart disease.53
There is little evidence therefore to suggest a true
causal relationship between the infectious agents linked
through association studies and atherosclerosis, and no
indication to routinely treat patients at risk with antimi-
crobial therapy. There may, however, be some role for
antibiotics in plaque modification independent of antimi-
crobial activity such as MMP inhibition. This will be
discussed further later in the review.Proteolysis- Targeting the Matrix
Metalloproteinases
Macrophages control many of the inflammatory processes
within the plaque and are responsible for the production of
proteolytic enzymes capable of degrading the extra cellular
matrix.2,54 The predominant proteolytic enzymes involved
in plaque disruption are the matrix metalloproteinases
(MMPs).55
MMPs are a family of enzymes characterised by binding
of zinc to active sites. All degrade components of the extra
cellular matrix and are divided into four main classes based
Figure 6 Immunostain demonstrating intense staining for
MMP9 in the shoulder of an unstable carotid plaque, in an
area of intense inflammatory infiltration.
Plaque Biology 513on their substrate specificity. While essential in healthy
individuals, playing a key role in processes such as wound
healing, there is considerable evidence linking MMPs to
a spectrum of disease states where matrix degradation
occurs, including atherosclerosis. MMPs have been impli-
cated in a number of vascular diseases, with particular
interest in aneurysm formation and plaque rupture.55,56
MMP9 levels in recently symptomatic plaques are sig-
nificantly higher in plaques from patients with recent
symptoms (Figs. 5 and 6).
This has provoked considerable interest in targeting
MMPs with selective and non-selective pharmacotherapy
to alter the balance of matrix accumulation and degrada-
tion. Early interest focussed on the potential for treating
periodontal disease, rheumatoid arthritis and malignancy.
Unfortunately, clinical results of MMP inhibition have not
matched their early promise.
MMP activity is controlled at a number of levels, pro-
viding opportunities for therapeutic manipulation (Fig. 7).
Firstly, MMP expression is determined at a transcriptional
level by various cytokines and growth factors.57 In a number
of tissue types, factors including IL-, TNF-a and PDGF stim-
ulate MMP expression, while other factors are inhibitory,
such as TGF-b. Steroids and heparin have also been shown
to reduce MMP expression.58
MMPs are secreted as inactive proenzymes, the activa-
tion of which represents a second level of control. The
major activator of MMPs is plasmin but many other factors
are involved including reactive oxygen species.59 Thirdly,
the occurrence of naturally occurring ‘tissue inhibitors of
MMPs’ (TIMPs) provides a further level of control, with over-
all proteolytic effect depending on the balance between
MMP and TIMP activity.60
Exogenously administered TIMPs are rapidly denatured
and tissue penetration is limited. Up-regulation of TIMP
production through cytokine administration or manipula-
tion may be feasible but the clinical application of this
approach seems likely to be hindered by the potential for1 2 3 4
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Figure 5 The level of MMP9 in carotid plaques from patients
with thrombo-embolic symptoms within 4 weeks of surgery
(group 4) was significantly higher the asymptomatic (group
1), and patients with symprtoms >6 months and 1e6 months
before surgery (groups 2 and 3 respectively. MMP9 represents
a potential target to prevent plaque destabilisation.significant side effects. In the longer term, a direct ap-
proach to TIMP expression through gene transfection
techniques has been suggested but this is currently limited
to animal models.12
Synthetic MMP inhibitors include tetracycline derived
antibiotics, anthracyclines and synthetic peptides. Results
in animal models, particularly of cancer and arthritis, have
shown promise but clinical results in humans have been less
impressive. In vascular disease, doxycycline has been
shown to penetrate the carotid plaque with some reduction
in MMP activity.61 Similarly, long term treatment in patients
with small aneurysms has been shown to reduce plasma
MMP9 levels but clinical benefit is unproven.62
Retinoids and steroids down regulate MMP transcription
but have proven to be ineffective in reducing coronary
restenosis following angioplasty. It has become clear that
matrix degradation within the unstable plaque is more
complex than initially perceived and many other factors are
involved than the MMP family. Furthermore, the longer
term effects of MMP inhibition deserve attention since
MMPs form a vital part of many normal physiological
processes such as wound healing.
Thrombomodulatory Factors
The role of thrombomodulatory factors in plaque instability
is complex and the cause/effect relationship unclear.
During the transient period of plaque instability, inflamma-
tion and proteolysis may be influenced, at least in part, by
up-regulation of thrombomodulatory factors. Acute plaque
disruption itself then leads to further activation of the
coagulation cascade and thrombus formation. Intraplaque
haemorrhage will also directly affect the expression of
thrombomodulatory factors. Conversely, thrombomodula-
tory factors also influence smooth muscle proliferation and
migration which is important in the healing process leading
into a quiescent phase following the period of instability.
The expression of thrombomodulatory factors has been
investigated in unstable coronary plaque, but the relation-
ship in carotid plaques is less well documented.63e65
Work in our unit has recently demonstrated that expres-
sion of thrombomodulatory genes is elevated following
Figure 7 Levels of control of MMP activity providing numerous potential targets for pharmacotherapy to alter the balance
between proteolysis and matrix synthesis.
514 I. Loftus, M. Thompsona clinical event, but that within one month levels of
expression are indistinguishable from asymptomatic
patients.
The most widely studied thrombomodulatory factor is
tissue factor, which represents the most potent pro-
thrombogenic factor identified in plaques. Tissue factor is
a glycoprotein, the expression of which is strongly induced
in activated macrophages and T-lymphocytes. Through
binding to factor VIIa, tissue factor directly activates the
coagulation cascade and has been suggested as a candidate
molecule for the link between plaque inflammation, in-
stability and thrombo-embolic phenomena.64 Tissue factor
pathway inhibitor is the major down-regulator of the pro-
coagulant activity of the TF-factor V11a complex.66 Previ-
ous studies have demonstrated increased expression of
tissue factor at sites of carotid and coronary plaque inflam-
mation.63,65 The level of tissue factor in coronary plaques
from patients with unstable angina is more than twice the
level in plaques from patients with stable angina. Similarly,
TFPI expression is up-regulated in plaques, and is expressed
by a variety of cell types including macrophages and
smooth muscle cells.
Fibrinolysis is activated by the 2 physiological plasmino-
gen activators, t-PA and u-PA. Tissue-type plasminogen
activator (t-PA) is a key enzyme mediating plasminogen to
plasmin conversion. Levels of t-PA and u-PA have been
demonstrated to be elevated in advanced atherosclerosis
and localised to areas in the fibrous cap populated by
macrophages, and areas lateral to the cap populated by
migrating smoothmuscle cells.67 Inhibition of the fibrinolytic
system occurs through PAI-1, which is also up-regulated in
atherosclerosis compared to normal tissue.68 The exact
role of PAI-1 and t-PA in the atherosclerotic lesion is unknownthough is likely to be multi-factorial. The balance of activa-
tion and inhibition of the fibrinolytic system is likely to shift
throughout the period of plaque instability and subsequent
stabilisation. This balance, or imbalance, may contribute
to plaque destabilisation and disruption particularly through
MMP activation and increased proteolysis, but conversely in-
creased u-PA and t-PA activity may counteract mural fibrin
deposition and facilitate plaque stability.
The precise roles of these individual factors remain
unclear and further work is required to elucidate the
effects of imbalances within the pro-coagulant and fibrino-
lytic systems in unstable plaques before there can be
a clear target for pharmacotherapy.Conclusion
So; plaque biology: interesting science or pharmacolog-
ical treasure trove? It would be reasonable to surmise
that, at present, more of the former than the latter. Our
understanding of the events surrounding plaque instabil-
ity has improved dramatically over the last 2 decades,
along with a clearer recognition of the potential impor-
tance of plaque modification in cardiovascular disease
prevention. Numerous associations have been made
between local and systemic factors perceived to be
important in plaque evolution and destabilisation, creat-
ing many targets for pharmacotherapy with many prom-
ising in vitro and animal models of disease regression and
prevention.
However, there has been a tendency to target single
agents, or isolated aspects of a much more complex
process, leading to poor clinical results in human studies.
Plaque Biology 515Similarly, there has been an emphasis (in recent years) on
the detection of cardiovascular biomarkers, coincident
with increasing pressure on the pharmaceutical industry
to identify novel anti-atherosclerotic agents- again with
disappointing results clinically.
Indirect evidence suggests that lipid lowering, b-
blockers and ACE inhibitors may all influence plaque
stability, but currently available markers of plaque stability
are relatively insensitive in detecting subtle plaque-stabil-
ising effects. Antioxidants, targeting infectious agents and
anti-proteolytic agents have promised much but delivered
little in terms of true clinical benefit. If successful new
agents are to be developed for, what remains an enormous
unmet clinical need, novel approaches based on the
growing insight into plaque biology need to be integrated
with novel clinical methods of detection and intervention.References
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